Skip to main content
Erschienen in: Journal of Bone and Mineral Metabolism 1/2010

01.01.2010 | Case Report

An autosomal dominant hypophosphatemic rickets phenotype in a Tunisian family caused by a new FGF23 missense mutation

verfasst von: Moez Gribaa, Mohamed Younes, Yosra Bouyacoub, Wided Korbaa, Ilhem Ben Charfeddine, Mongi Touzi, Labiba Adala, Ons Mamay, Naceur Bergaoui, Ali Saad

Erschienen in: Journal of Bone and Mineral Metabolism | Ausgabe 1/2010

Einloggen, um Zugang zu erhalten

Abstract

Autosomal dominant hypophosphatemic rickets (ADHR) is a rare disease, characterized by isolated renal phosphate wasting, hypophosphatemia, and inappropriately normal 1,25-dihydroxyvitamin D3 (calcitriol) levels. This syndrome involves rickets with bone deformities in childhood and osteomalacia, osteoporosis, articular and para-articular pain, and fatigue in adulthood. It is caused by mutations in a consensus sequence for proteolytic cleavage of the FGF23 protein. Normally, this protein actively regulates phosphate homeostasis. Here we report a Tunisian family in which one parent and three children show clinical and biological features of ADHR. Mutation analysis of the FGF23 gene finds a heterozygous substitution of the C at position 526 by a T (526 C → T), leading to an amino acid replacement of the FGF23 protein (R176W) at position 176. This causative new mutation is located in the consensus sequence for the proteolytic cleavage domain. These results confirm the importance of this site in FGF23 function and its essential role in ADHR physiopathology.
Literatur
1.
Zurück zum Zitat Yu X, White KE (2005) FGF23 and disorders of phosphate homeostasis. Cytokine Growth Factor Rev 16:221–232CrossRefPubMed Yu X, White KE (2005) FGF23 and disorders of phosphate homeostasis. Cytokine Growth Factor Rev 16:221–232CrossRefPubMed
2.
Zurück zum Zitat Carpenter TO (1997) New perspectives on the biology and treatment of X-linked hypophosphatemic rickets. Pediatr Clin N Am 44:443–466CrossRef Carpenter TO (1997) New perspectives on the biology and treatment of X-linked hypophosphatemic rickets. Pediatr Clin N Am 44:443–466CrossRef
3.
Zurück zum Zitat Laroche M (2001) Phosphate, the renal tubule, and the musculoskeletal system. Joint Bone Spine 68:211–215CrossRefPubMed Laroche M (2001) Phosphate, the renal tubule, and the musculoskeletal system. Joint Bone Spine 68:211–215CrossRefPubMed
4.
Zurück zum Zitat ADHR Consortium (2000) Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 26:345–348CrossRef ADHR Consortium (2000) Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 26:345–348CrossRef
5.
Zurück zum Zitat Bielesz B, Klaushofer K, Oberbauer R (2004) Renal phosphate loss in hereditary and acquired disorders of bone mineralization. Bone 35:1229–1239CrossRefPubMed Bielesz B, Klaushofer K, Oberbauer R (2004) Renal phosphate loss in hereditary and acquired disorders of bone mineralization. Bone 35:1229–1239CrossRefPubMed
6.
Zurück zum Zitat Laroche M, Boyer JF (2005) Phosphate diabetes, tubular phosphate reabsorption and phosphatonins. Joint Bone Spine 72:376–381CrossRefPubMed Laroche M, Boyer JF (2005) Phosphate diabetes, tubular phosphate reabsorption and phosphatonins. Joint Bone Spine 72:376–381CrossRefPubMed
7.
Zurück zum Zitat Walton RJ, Bijvoet OL (1975) Nomogram for derivation of renal threshold phosphate concentration. Lancet 2:309–310CrossRefPubMed Walton RJ, Bijvoet OL (1975) Nomogram for derivation of renal threshold phosphate concentration. Lancet 2:309–310CrossRefPubMed
8.
Zurück zum Zitat Bai XY, Miao D, Goltzman D, Karaplis AC (2003) The autosomal dominant hypophosphatemic rickets R176Q mutation in fibroblast growth factor 23 resists proteolytic cleavage and enhances in vivo biological potency. J Biol Chem 278:9843–9849CrossRefPubMed Bai XY, Miao D, Goltzman D, Karaplis AC (2003) The autosomal dominant hypophosphatemic rickets R176Q mutation in fibroblast growth factor 23 resists proteolytic cleavage and enhances in vivo biological potency. J Biol Chem 278:9843–9849CrossRefPubMed
9.
Zurück zum Zitat Econs MJ, McEnery PT (1997) Autosomal dominant hypophosphatemic rickets/osteomalacia: clinical characterization of a novel renal phosphate-wasting disorder. J Clin Endocrinol Metab 82:674–681CrossRefPubMed Econs MJ, McEnery PT (1997) Autosomal dominant hypophosphatemic rickets/osteomalacia: clinical characterization of a novel renal phosphate-wasting disorder. J Clin Endocrinol Metab 82:674–681CrossRefPubMed
10.
Zurück zum Zitat Consortium HYP (1995) A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. Nat Genet 11:130–136CrossRef Consortium HYP (1995) A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. Nat Genet 11:130–136CrossRef
11.
Zurück zum Zitat Caruana RJ, Buckalew VM Jr (1988) The syndrome of distal (type 1) renal tubular acidosis. Clinical and laboratory findings in 58 cases. Medicine (Baltim) 67:84–99 Caruana RJ, Buckalew VM Jr (1988) The syndrome of distal (type 1) renal tubular acidosis. Clinical and laboratory findings in 58 cases. Medicine (Baltim) 67:84–99
12.
Zurück zum Zitat Clarke BL, Wynne AG, Wilson DM, Fitzpatrick LA (1995) Osteomalacia associated with adult Fanconi’s syndrome: clinical and diagnostic features. Clin Endocrinol (Oxf) 43:479–490CrossRef Clarke BL, Wynne AG, Wilson DM, Fitzpatrick LA (1995) Osteomalacia associated with adult Fanconi’s syndrome: clinical and diagnostic features. Clin Endocrinol (Oxf) 43:479–490CrossRef
13.
Zurück zum Zitat Econs MJ, McEnery PT, Lennon F, Speer MC (1997) Autosomal dominant hypophosphatemic rickets is linked to chromosome 12p13. J Clin Invest 100:2653–2657CrossRefPubMed Econs MJ, McEnery PT, Lennon F, Speer MC (1997) Autosomal dominant hypophosphatemic rickets is linked to chromosome 12p13. J Clin Invest 100:2653–2657CrossRefPubMed
14.
Zurück zum Zitat Kaplan FS, Soffer SR, Fallon MD, Haddad JG, Dalinka M, Raffensperger EC (1988) Osteomalacia as a very late manifestation of primary hyperparathyroidism. Clin Orthop Relat Res 228:26–32PubMed Kaplan FS, Soffer SR, Fallon MD, Haddad JG, Dalinka M, Raffensperger EC (1988) Osteomalacia as a very late manifestation of primary hyperparathyroidism. Clin Orthop Relat Res 228:26–32PubMed
15.
Zurück zum Zitat Lyles KW, Drezner MK (1982) Parathyroid hormone effects on serum 1, 25-dihydroxyvitamin D levels in patients with X-linked hypophosphatemic rickets: evidence for abnormal 25-hydroxyvitamin D-1-hydroxylase activity. J Clin Endocrinol Metab 54:638–644CrossRefPubMed Lyles KW, Drezner MK (1982) Parathyroid hormone effects on serum 1, 25-dihydroxyvitamin D levels in patients with X-linked hypophosphatemic rickets: evidence for abnormal 25-hydroxyvitamin D-1-hydroxylase activity. J Clin Endocrinol Metab 54:638–644CrossRefPubMed
16.
Zurück zum Zitat Monte Neto JT, Sesso R, Kirsztajn GM, Da Silva LC, De Carvalho AB, Pereira AB (1991) Osteomalacia secondary to renal tubular acidosis in a patient with primary Sjogren’s syndrome. Clin Exp Rheumatol 9:625–627PubMed Monte Neto JT, Sesso R, Kirsztajn GM, Da Silva LC, De Carvalho AB, Pereira AB (1991) Osteomalacia secondary to renal tubular acidosis in a patient with primary Sjogren’s syndrome. Clin Exp Rheumatol 9:625–627PubMed
17.
Zurück zum Zitat Polisson RP, Martinez S, Khoury M, Harrell RM, Lyles KW, Friedman N, Harrelson JM, Reisner E, Drezner MK (1985) Calcification of entheses associated with X-linked hypophosphatemic osteomalacia. N Engl J Med 313:1–6PubMed Polisson RP, Martinez S, Khoury M, Harrell RM, Lyles KW, Friedman N, Harrelson JM, Reisner E, Drezner MK (1985) Calcification of entheses associated with X-linked hypophosphatemic osteomalacia. N Engl J Med 313:1–6PubMed
18.
Zurück zum Zitat Tieder M, Modai D, Shaked U, Samuel R, Arie R, Halabe A, Maor J, Weissgarten J, Averbukh Z, Cohen N, Edelstein S, Liberman U (1987) “Idiopathic” hypercalciuria and hereditary hypophosphatemic rickets. Two phenotypical expressions of a common genetic defect. N Engl J Med 316:125–129PubMedCrossRef Tieder M, Modai D, Shaked U, Samuel R, Arie R, Halabe A, Maor J, Weissgarten J, Averbukh Z, Cohen N, Edelstein S, Liberman U (1987) “Idiopathic” hypercalciuria and hereditary hypophosphatemic rickets. Two phenotypical expressions of a common genetic defect. N Engl J Med 316:125–129PubMedCrossRef
19.
Zurück zum Zitat Benet-Pages A, Lorenz-Depiereux B, Zischka H, White KE, Econs MJ, Strom TM (2004) FGF23 is processed by proprotein convertases but not by PHEX. Bone 35:455–462CrossRefPubMed Benet-Pages A, Lorenz-Depiereux B, Zischka H, White KE, Econs MJ, Strom TM (2004) FGF23 is processed by proprotein convertases but not by PHEX. Bone 35:455–462CrossRefPubMed
20.
Zurück zum Zitat Liu S, Guo R, Simpson LG, Xiao ZS, Burnham CE, Quarles LD (2003) Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX. J Biol Chem 278:37419–37426CrossRefPubMed Liu S, Guo R, Simpson LG, Xiao ZS, Burnham CE, Quarles LD (2003) Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX. J Biol Chem 278:37419–37426CrossRefPubMed
21.
Zurück zum Zitat White KE, Carn G, Lorenz-Depiereux B, Benet-Pages A, Strom TM, Econs MJ (2001) Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int 60:2079–2086CrossRefPubMed White KE, Carn G, Lorenz-Depiereux B, Benet-Pages A, Strom TM, Econs MJ (2001) Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int 60:2079–2086CrossRefPubMed
22.
Zurück zum Zitat Benet-Pages A, Orlik P, Strom TM, Lorenz-Depiereux B (2005) An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. Hum Mol Genet 14:385–390CrossRefPubMed Benet-Pages A, Orlik P, Strom TM, Lorenz-Depiereux B (2005) An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. Hum Mol Genet 14:385–390CrossRefPubMed
23.
Zurück zum Zitat Larsson T, Davis SI, Garringer HJ, Mooney SD, Draman MS, Cullen MJ, White KE (2005) Fibroblast growth factor-23 mutants causing familial tumoral calcinosis are differentially processed. Endocrinology 146:3883–3891CrossRefPubMed Larsson T, Davis SI, Garringer HJ, Mooney SD, Draman MS, Cullen MJ, White KE (2005) Fibroblast growth factor-23 mutants causing familial tumoral calcinosis are differentially processed. Endocrinology 146:3883–3891CrossRefPubMed
25.
Zurück zum Zitat Liu S, Vierthaler L, Tang W, Zhou J, Quarles LD (2008) FGFR3 and FGFR4 do not mediate renal effects of FGF23. J Am Soc Nephrol 19:2342–2350CrossRefPubMed Liu S, Vierthaler L, Tang W, Zhou J, Quarles LD (2008) FGFR3 and FGFR4 do not mediate renal effects of FGF23. J Am Soc Nephrol 19:2342–2350CrossRefPubMed
26.
Zurück zum Zitat Yamazaki Y, Tamada T, Kasai N, Urakawa I, Aono Y, Hasegawa H, Fujita T, Kuroki R, Yamashita T, Fukumoto S, Shimada T (2008) Anti-FGF23 neutralizing antibodies show the physiological role and structural features of FGF23. J Bone Miner Res 23:1509–1518CrossRefPubMed Yamazaki Y, Tamada T, Kasai N, Urakawa I, Aono Y, Hasegawa H, Fujita T, Kuroki R, Yamashita T, Fukumoto S, Shimada T (2008) Anti-FGF23 neutralizing antibodies show the physiological role and structural features of FGF23. J Bone Miner Res 23:1509–1518CrossRefPubMed
Metadaten
Titel
An autosomal dominant hypophosphatemic rickets phenotype in a Tunisian family caused by a new FGF23 missense mutation
verfasst von
Moez Gribaa
Mohamed Younes
Yosra Bouyacoub
Wided Korbaa
Ilhem Ben Charfeddine
Mongi Touzi
Labiba Adala
Ons Mamay
Naceur Bergaoui
Ali Saad
Publikationsdatum
01.01.2010
Verlag
Springer Japan
Erschienen in
Journal of Bone and Mineral Metabolism / Ausgabe 1/2010
Print ISSN: 0914-8779
Elektronische ISSN: 1435-5604
DOI
https://doi.org/10.1007/s00774-009-0111-5

Weitere Artikel der Ausgabe 1/2010

Journal of Bone and Mineral Metabolism 1/2010 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.